The cutting-edge progress of novel biomedicines in ovulatory dysfunction therapy.
10.1016/j.apsb.2025.08.008
- Author:
Xuzhi LIANG
1
;
Shiyu ZHANG
1
;
Dahai LI
1
;
Hao LIANG
1
;
Yueping YAO
1
;
Xiuhong XIA
1
;
Hang YU
1
;
Mingyang JIANG
2
;
Ying YANG
3
;
Ming GAO
4
;
Lin LIAO
5
;
Jiangtao FAN
1
Author Information
1. Department of Gynecology, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
2. Department of Orthopaedic Surgery, Yong Loo Lin School of Medicine, National University of Singapore 117510, Singapore.
3. Department of Reproductive Medicine, Yunlin First People's Hospital, Yulin 537000, China.
4. Life Sciences Institute, Guangxi Medical University, Nanning 530021, China.
5. Department of Clinical Laboratory, the First Affiliated Hospital of Guangxi Medical University, Key Laboratory of Clinical Laboratory Medicine of Guangxi Department of Education, Nanning 530021, China.
- Publication Type:Review
- Keywords:
Controlled drug release;
Drug delivery system;
Infertility therapy;
Novel biomedicines;
Ovarian microenvironment reprogramming;
Ovulatory dysfunction
- From:
Acta Pharmaceutica Sinica B
2025;15(10):5145-5166
- CountryChina
- Language:English
-
Abstract:
Ovulatory dysfunction (OD) is one of the main causes of infertility in women of childbearing age, which not only affects their reproductive ability, but also physical and mental health. Traditional treatment strategies have limited efficacies, and the emergence of biomedicines provides a promising alternative solution via the strategies of combining engineered design with modern advanced technology. This review explores the pathophysiological characteristics and related induction mechanisms of OD, and evaluates the current cutting-edge advances in its treatments. It emphasizes the potentials of biomedicines strategies such as hydrogels, nanoparticles and extracellular vesicles in improving therapeutic precision and efficacy. By mimicking natural physiological processes, and achieving controlled drug release, these advanced drug carriers are expected to address the challenges in ovarian microenvironment reprogramming, tissue repair, and metabolic and immune regulation. Despite the promising progress, there are still challenges in terms of biomedical complexity, differences between animal models and human physiology, and the demand for intelligent drug carriers in the therapy of OD. Future researches are mainly dedicated to developing precise personalized biomedicines in OD therapy through interdisciplinary collaboration, promoting the development of reproductive regenerative medicine.
